Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Ultragenyx Q3 Revenue Reaches $173 Million as Net Loss Narrows 34%

Ultragenyx Pharmaceutical reported a steady 8.1% year-over-year increase in revenue for the third quarter of 2026, totaling $173.00 million. The company achieved a significant reduction in its net loss, which improved from $180.00 million to $118.00 million as management focused on cost discipline and clinical milestones.

Research, healthcare, medicine, microscope. Stock photo illustrating Ultragenyx Pharmaceutical's financial results story.
Ultragenyx Pharmaceutical Inc. · Photo: geralt / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 173.00160.00
Pretax Income -127.00-179.00
Net Income -118.00-180.00
Diluted EPS -1.16-1.81
Net Income YoY
+34.4%

Key highlights

  • Quarterly revenue grew to $173.00 million from $160.00 million in the prior year
  • Net loss narrowed by 34.4% year-over-year to $118.00 million
  • Diluted earnings per share improved to -$1.16 compared to -$1.81 in Q3 2025
  • Management reaffirmed full-year 2026 revenue guidance of $730 million to $760 million
  • Sale of the FAYUVI Priority Review Voucher for $203 million is expected to close in November 2026

How the Period Went

Ultragenyx Pharmaceutical reported an 8.1% year-over-year increase in revenue for the third quarter of 2026, reaching $173.00 million compared to $160.00 million in the same period last year. This top-line growth was accompanied by a significant improvement in the bottom line, as the company narrowed its net loss to $118.00 million from $180.00 million in the prior-year quarter. This 34.4% year-over-year reduction in net loss was reflected in the diluted earnings per share, which improved to -$1.16 from -$1.81. The results indicate a steady expansion of the commercial product portfolio alongside a focus on reducing the quarterly burn rate.

Margins and Profitability

  • Pretax loss improved to $127.00 million, down from a $179.00 million loss in Q3 2025.
  • The company maintained its commitment to managing operating expenses, specifically targeting R&D and SG&A reductions for 2027.
  • Non-operating items and tax benefits contributed to a narrower net loss relative to the pretax loss during the period.
  • The company's liquidity position is expected to be bolstered by the $203 million sale of the FAYUVI Priority Review Voucher scheduled for late 2026.

Business Overview

Ultragenyx Pharmaceutical is a biopharmaceutical firm focused on the identification, acquisition, and development of novel therapies for rare and ultra-rare genetic diseases. The company operates within the biotechnology sector, serving niche patient populations with high unmet medical needs. Its commercialized portfolio includes treatments for metabolic and bone disorders, such as Crysvita and Dojolvi. By focusing on rare conditions, the company navigates a specialized regulatory landscape and serves end markets characterized by high barriers to entry and limited competition, while its clinical pipeline continues to explore gene therapies and enzyme replacement treatments for complex genetic conditions.

Financial Context

  • The quarterly revenue of $173.00 million represents a sequential decline from the $214.0 million reported in the second quarter of 2026.
  • Management reaffirmed its full-year 2026 revenue target of $730 million to $760 million, implying a strong anticipated performance in the final quarter.
  • The stock currently carries a Relative Strength Index (RSI) of 54.0, suggesting a neutral market position following a 33.24% decline over the previous quarter.
  • Data from the Phase 3 Enh3ance study for DTX301 in OTC deficiency is expected in the first half of 2027, representing a major upcoming clinical milestone.
Ultragenyx Pharmaceutical Inc. share price · last month
Line chart of Ultragenyx Pharmaceutical Inc.'s share price over the last month, from $15.07 on 19 Oct → $15.90 on 16 Nov; our story on 4 Nov at $16.63.

Down 4.4% since our story on 4 Nov: $16.63 when we broke it → $15.90 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$15.07
20 Oct$16.02
21 Oct$15.92
22 Oct$15.95
23 Oct$15.65
26 Oct$16.08
27 Oct$16.75
28 Oct$17.20
29 Oct$16.78
30 Oct$16.10
2 Nov$16.30
3 Nov$16.63
4 Nov$17.16
5 Nov$15.57
6 Nov$15.43
9 Nov$16.41
10 Nov$16.14
11 Nov$16.70
12 Nov$16.27
13 Nov$16.08
16 Nov$15.90
Recent quarters and guidance
DateAnnouncementAmount
03 Nov 2026Q3 2026 total revenueSource: ir.ultragenyx.com$173.0 Million
04 Aug 2026Q2 2026 total revenueSource: ir.ultragenyx.com$214.0 Million
05 May 2026Q1 2026 total revenueSource: SEC filing$136.0 Million
12 Feb 2026Q4 2025 total revenueSource: ir.ultragenyx.com$207.0 Million
04 Nov 2025Q3 2025 total revenueSource: ir.ultragenyx.com$160.0 Million
05 Aug 2025Q2 2025 total revenueSource: ir.ultragenyx.com$166.0 Million
Ultragenyx Pharmaceutical Inc. · financial snapshot
Share price$16.63
Market cap$1.7B
Revenue (annual)$673M
1-month price change+9.26%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Ultragenyx Pharmaceutical Inc. announcing its third quarter 2026 financial results.

Read the filing ↗
All Ultragenyx Pharmaceutical Inc. filings and newsView all →

Track Ultragenyx Pharmaceutical Inc. live

Get the next Ultragenyx Pharmaceutical Inc. SEC filing seconds after it lands.

More from Ultragenyx Pharmaceutical Inc.

All →

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.